BR112023016627A2 - Ensaio de depuração - Google Patents
Ensaio de depuraçãoInfo
- Publication number
- BR112023016627A2 BR112023016627A2 BR112023016627A BR112023016627A BR112023016627A2 BR 112023016627 A2 BR112023016627 A2 BR 112023016627A2 BR 112023016627 A BR112023016627 A BR 112023016627A BR 112023016627 A BR112023016627 A BR 112023016627A BR 112023016627 A2 BR112023016627 A2 BR 112023016627A2
- Authority
- BR
- Brazil
- Prior art keywords
- fragment
- sfm
- disease marker
- cells
- agent
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 239000003550 marker Substances 0.000 abstract 7
- 239000012634 fragment Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000003834 intracellular effect Effects 0.000 abstract 3
- 238000006555 catalytic reaction Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010057249 Phagocytosis Diseases 0.000 abstract 1
- 230000006759 inflammatory activation Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000242 pagocytic effect Effects 0.000 abstract 1
- 230000008782 phagocytosis Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Temperature-Responsive Valves (AREA)
Abstract
ensaio de depuração. um método ex vivo para determinar o efeito de um agente na catálise por uma célula do sistema fagocitário mononuclear (sfm) de um produto marcador de doença e/ou pelo menos um fragmento do mesmo associado com neurodegeneração e/ou ativação inflamatória. o método compreende: i) manter uma amostra de células do sfm sob condições nas quais as células do sfm permaneçam vivas, ii) expor a amostra de células do sfm a um agente e um produto marcador de doença, para permitir a fagocitose do produto marcador de doença pelas células do sfm, iii) detectar a quantidade intracelular do produto marcador da doença e/ou pelo menos um fragmento do mesmo na amostra de células do sfm, e iv) comparar a quantidade intracelular do produto marcador da doença e/ou pelo menos um fragmento do mesmo com uma quantidade intracelular do mesmo produto marcador de doença e/ou pelo menos um fragmento do mesmo medido em células mps de controle na ausência do agente. o efeito do agente na catálise por células do sfm do produto marcador da doença e/ou pelo menos um fragmento do mesmo é determinado pelo resultado da comparação da etapa iv).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21161384 | 2021-03-08 | ||
| PCT/EP2022/055950 WO2022189463A1 (en) | 2021-03-08 | 2022-03-08 | Clearance assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016627A2 true BR112023016627A2 (pt) | 2023-09-26 |
Family
ID=74867403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016627A BR112023016627A2 (pt) | 2021-03-08 | 2022-03-08 | Ensaio de depuração |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240168011A1 (pt) |
| EP (1) | EP4305415A1 (pt) |
| JP (1) | JP2024508959A (pt) |
| CN (1) | CN117098993A (pt) |
| AU (1) | AU2022233849A1 (pt) |
| BR (1) | BR112023016627A2 (pt) |
| CA (1) | CA3210214A1 (pt) |
| MX (1) | MX2023009903A (pt) |
| WO (1) | WO2022189463A1 (pt) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1944314A1 (en) * | 2007-01-11 | 2008-07-16 | Philipps-Universität Marburg | Diagnosis of Alzheimer's disease and other neurodementing disorders |
| GB0802851D0 (en) | 2008-02-15 | 2008-03-26 | Medinnova As | Diagnostic method |
| PL2282758T3 (pl) * | 2008-04-29 | 2019-04-30 | Bioarctic Ab | Przeciwciała i szczepionki do zastosowania w terapeutycznych i diagnostycznych sposobach dla zaburzeń związanych z alfa-synukleiną |
| MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| WO2012004276A2 (en) * | 2010-07-06 | 2012-01-12 | Fondazione Telethon | Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits |
| DK2646462T3 (en) * | 2010-11-29 | 2017-07-03 | Akershus Univ | METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY |
| US20140154180A1 (en) * | 2011-07-14 | 2014-06-05 | The Regents Of The University Of California | Pharmacophores for Amyloid Fibers Involved in Alzheimer's Disease |
| WO2015184105A1 (en) * | 2014-05-29 | 2015-12-03 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases |
| JP7273723B2 (ja) * | 2016-12-20 | 2023-05-15 | オリゴメリックス インコーポレイテッド | タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法 |
| MX2021012572A (es) | 2019-04-18 | 2022-01-18 | Akershus Univ Hf | Terapia de combinacion que comprende un agonista de ffar4 y un agonista de nachr alfa-7 o modulador positivo. |
-
2022
- 2022-03-08 AU AU2022233849A patent/AU2022233849A1/en active Pending
- 2022-03-08 CN CN202280019873.XA patent/CN117098993A/zh active Pending
- 2022-03-08 CA CA3210214A patent/CA3210214A1/en active Pending
- 2022-03-08 JP JP2023554382A patent/JP2024508959A/ja active Pending
- 2022-03-08 BR BR112023016627A patent/BR112023016627A2/pt unknown
- 2022-03-08 MX MX2023009903A patent/MX2023009903A/es unknown
- 2022-03-08 EP EP22711950.0A patent/EP4305415A1/en active Pending
- 2022-03-08 US US18/549,388 patent/US20240168011A1/en active Pending
- 2022-03-08 WO PCT/EP2022/055950 patent/WO2022189463A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009903A (es) | 2023-09-04 |
| CN117098993A (zh) | 2023-11-21 |
| AU2022233849A9 (en) | 2023-10-26 |
| WO2022189463A1 (en) | 2022-09-15 |
| CA3210214A1 (en) | 2022-09-15 |
| EP4305415A1 (en) | 2024-01-17 |
| AU2022233849A1 (en) | 2023-10-12 |
| US20240168011A1 (en) | 2024-05-23 |
| JP2024508959A (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kramár et al. | Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity | |
| Ginde et al. | Vitamin D insufficiency and sepsis severity in emergency department patients with suspected infection | |
| Cătoi et al. | Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with insulin resistance, oxidative stress and chronic inflammation | |
| Müller et al. | Endogenous Ca2+ buffer concentration and Ca2+ microdomains in hippocampal neurons | |
| Shinjo et al. | Disruption of the mitochondria-associated ER membrane (MAM) plays a central role in palmitic acid–induced insulin resistance | |
| Wirnsberger et al. | Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense | |
| BR112018073178A2 (pt) | método, matriz e uso dos mesmos | |
| Lopes-Pires et al. | Zinc regulates reactive oxygen species generation in platelets | |
| BR112013032354A2 (pt) | Composições e métodos para diagnóstico e monitoração de hipertireoidismo em um felino | |
| BR112016028534A2 (pt) | ceramidas e seu uso em diagnosticar cvd | |
| Blanco et al. | Maternal biomarkers of methylation status and non-syndromic orofacial cleft risk: a meta-analysis | |
| BR112012009291A2 (pt) | sistema de reconhecimento de subenchimento para um biossensor | |
| Giltaire et al. | HB‐EGF synthesis and release induced by cholesterol depletion of human epidermal keratinocytes is controlled by extracellular atp and involves both p38 and ERK1/2 signaling pathways | |
| BR112015024780A2 (pt) | metodo para determinar radiosensibilidade | |
| BR112015007032A2 (pt) | sistema e método para determinação de concentrações de glicose insensíveis a hematócritos | |
| BR112018071430A2 (pt) | compensação de varreduras de tomografia de coerência ótica | |
| Li et al. | GYY4137 alleviates sepsis-induced acute lung injury in mice by inhibiting the PDGFRβ/Akt/NF-κB/NLRP3 pathway | |
| Nigra et al. | Alterations of hemorheological parameters and tubulin content in erythrocytes from diabetic subjects | |
| BR112023016627A2 (pt) | Ensaio de depuração | |
| BR112022008068A2 (pt) | Métodos para auxiliar na avaliação de risco de um paciente com suspeita de sepse e método implementado por computador para a avaliação de um paciente com suspeita de sepse | |
| Mitrović et al. | 17β-estradiol-induced synaptic rearrangements are accompanied by altered ectonucleotidase activities in male rat hippocampal synaptosomes | |
| Siddappa et al. | Mechanistic target of rapamycin (MTOR) signaling during ovulation in mice | |
| KANG et al. | An effect of the secondary stroke prevention education program on self-care of acute ischemic stroke patients | |
| Ikizawa et al. | Mitochondria directly sense osmotic stress to trigger rapid metabolic remodeling via regulation of pyruvate dehydrogenase phosphorylation | |
| BR112021022532A8 (pt) | Controle de variabilidade de analito entre amostras em matrizes biológicas complexas |